FullHope Biomedical

Executive Summary

FullHope Biomedical (FHB) is a Taiwan-based private biotech company founded in 2012, specializing in cell-based immunotherapies for oncology and autoimmune diseases. Leveraging a GTP-certified laboratory and AI-driven immune profiling, FHB develops autologous cell products and personalized immunomodulation strategies. The company's platform aims to harness the patient's own immune system to target cancer and autoimmune conditions, potentially offering more precise and durable responses compared to conventional therapies. Currently in Phase 1 clinical stage, FHB has a lean team of 50-200 employees and operates from its headquarters in New Taipei City. Despite being early-stage, FullHope Biomedical's differentiated approach combining AI with cellular immunotherapy positions it in a high-growth niche. The company is poised to generate initial clinical data from its lead programs, which could de-risk its platform and attract strategic partnerships or licensing deals. However, as a private company with limited disclosed financials and no public pipeline details, visibility into near-term milestones is low. Key catalysts include the release of Phase 1 safety and efficacy data, expansion into Phase 2 trials, and potential collaborations with larger pharma or diagnostics firms. Given its early stage and the inherent risks in cell therapy development, conviction is moderate.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 clinical data readout for lead autologous cell therapy candidate60% success
• 2027Partnership or licensing agreement with a larger pharmaceutical or diagnostics company40% success
• 2026Series B or later-stage funding round to support pipeline expansion65% success